What Topos Bio does

Topos Bio is a privately held, pre-revenue biotechnology company founded in 2025 and headquartered in San Francisco that is building an AI-native drug discovery platform for intrinsically disordered proteins (IDPs). IDPs comprise roughly one-third of the human proteome and lack stable binding pockets, which makes them inaccessible to conventional lock-and-key drug design and traditional static-structure predictors such as AlphaFold. The company was co-founded by Ryan Zarcone, a UC Berkeley-trained biophysicist and former AI lead at Fountain Therapeutics who serves as CEO, and Amir Khosrowshahi, former CTO of Intel AI and co-founder of Nervana (acquired by Intel for $400M).

The core product is the Topos-1 foundation model, an all-atom generative model that produces physically realistic conformational ensembles capturing protein dynamics, generating tens of thousands of conformers in minutes. Topos-1 reportedly outperforms AlphaFold-2, Chai-1, and Boltz-2x on IDP-specific benchmarks (40%+ lower SAXS-derived radius of gyration error, 30%+ lower NMR chemical shift error across 104 IDPs) and runs roughly 1,000x faster than atomistic molecular dynamics. The platform integrates this modeling layer with a generative chemistry pipeline for small-molecule design and an in-house wet lab for experimental validation, creating a flywheel in which experimental data refines the model. The proprietary IDP-focused training dataset, combining physics-based simulations with internal measurements, is positioned as a durable data advantage.

The business model is structured around licensing and co-development of therapeutic candidates rather than platform SaaS or services revenue. Initial therapeutic programs focus on neurodegenerative disorders (Alzheimer's, Parkinson's via alpha-synuclein in partnership with Gladstone Institutes), with oncology (prostate cancer) and metabolic diseases as subsequent verticals. The company has raised $10.5M in seed funding (January 2026) led by Boldstart Ventures, Threshold Ventures, and Neo, with angels including Dara Khosrowshahi and Naveen Rao, and has added Dalriada Drug Discovery as a proteomics and mass spectrometry validation partner.

Name

Topos Bio

Legal name

Topos Bio

Website

https://toposbio.ai

Company type

Private

Founded year

2025

Operating status

Operating

Short description

Topos Bio is a San Francisco-based, pre-revenue AI-native biotechnology company developing the Topos-1 foundation model and drug discovery platform to design small molecules against intrinsically disordered proteins implicated in neurodegenerative disease, oncology, and metabolic disorders.

Ownership category

akta.pro rank

Product category

AI Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industries

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA), Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL)

Keywords

• AI drug discovery
• Computational biology
• Intrinsically disordered proteins
• Foundation model
• Generative chemistry

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Therapeutic Development and Licensing: Pre-revenue company developing AI-driven therapeutics for intrinsically disordered proteins. Revenue model will likely involve licensing drug candidates to pharmaceutical partners, co-development agreements, or eventual product commercialization. Initial therapeutic programs focus on neurodegenerative disorders (Alzheimer's, Parkinson's) followed by oncology and metabolic diseases.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Topos Bio builds an AI-native integrated drug discovery platform that combines the Topos-1 all-atom foundation model with generative chemistry and wet lab validation to design small-molecule therapeutics against intrinsically disordered proteins (IDPs). The platform models IDPs as dynamic conformational ensembles rather than static structures, enabling rational drug design for targets previously considered "undruggable" in neurodegenerative diseases, oncology, and metabolic disorders.

Product overview

Topos Bio is an AI-native drug discovery company offering an integrated platform that combines the Topos-1 foundation model with generative chemistry and wet lab validation. Topos-1 generates all-atom conformational ensembles for intrinsically disordered proteins (IDPs), capturing their dynamic behavior that traditional static structure predictors miss. The platform then uses these ensembles to identify binding opportunities and design small molecule drug candidates, with an integrated wet lab for experimental validation. The company focuses on neurodegenerative disorders (Alzheimer's, Parkinson's), oncology (prostate cancer), and metabolic diseases as initial therapeutic areas.

Differentiator

Problem solved

Functional benefit

Brands

• Topos-1: All-atom foundation model for intrinsically disordered proteins that generates physically realistic conformational ensembles for flexible proteins at high speed, enabling ensemble-level modeling for drug discovery and research applications.

Products and services

• Topos Bio AI Drug Discovery Platform AI-native integrated drug discovery platform that models intrinsically disordered proteins (IDPs) as dynamic conformational ensembles rather than static structures, enabling rational drug design for targets previously considered undruggable. Combines the Topos-1 foundation model with generative chemistry capabilities and integrated wet lab validation for pharmaceutical and biotech partners.
• Topos-1 Foundation Model All-atom foundation model purpose-built for intrinsically disordered proteins (IDPs) that generates physically realistic conformational ensembles at approximately 1,000x the speed of atomistic molecular dynamics. Outperforms AlphaFold, Chai-1, and Boltz-2x by 40%+ on SAXS radius of gyration error and 30%+ on NMR chemical shift error across 104 IDPs. Trained on a proprietary dataset combining large-scale physics-based simulations and internal experimental measurements specifically designed for IDPs.

Quantifiable outcome

• Topos-1 reduces normalized radius of gyration error by at least 40% compared to leading structure prediction models (BioEmu, Chai-1, Boltz-2x, AlphaFold-2) across 104 IDPs
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Dalriada Drug DiscoverycoreTechnology or Integration · 17 March 2026Research collaboration to accelerate experimental validation for intrinsically disordered protein (IDP) drug discovery using advanced protein mass spectrometry and proteomics. Topos Bio leverages Dalriada's infrastructure and iCLASS platform to generate high-resolution data on protein-small molecule interactions to guide iterative drug design and prioritization.
• Gladstone InstitutescoreStrategic or Co-development Partner · 8 January 2026Strategic collaboration focused on discovering novel modulators for alpha-synuclein, a disordered protein central to Parkinson's disease pathology. Combines Gladstone's advanced imaging and disease modeling capabilities with Topos Bio's computational methods for translational research in neurodegenerative disease.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Atomwise: Atomwise applies AI (AtomNet) to structure-based small molecule drug design across multiple therapeutic areas. It is a direct peer in AI-driven small-molecule discovery with a similar partnership-heavy GTM model targeting pharma licensing deals.
• Iambic Therapeutics: Iambic (formerly Entasis) develops AI-driven therapeutics using physics-informed neural networks for structure-based design. It is a direct peer applying AI to protein-ligand modeling and small-molecule discovery, with overlapping technology stack in protein dynamics modeling and a comparable early-stage profile.
• Recursion Pharmaceuticals: Recursion uses AI and high-throughput wet-lab experimentation to discover drugs across multiple therapeutic areas. It is a direct peer in the AI-native drug discovery category, with a more mature pipeline and larger capital base, but overlapping business model of combining computational prediction with experimental validation.
• Insitro: Insitro is a well-capitalized AI-driven drug discovery company combining machine learning with high-throughput biology to develop therapeutics. It is a direct peer to Topos Bio as both apply AI/ML to target identification and small-molecule design, though Insitro's initial focus has been on generative models for chemistry and induced pluripotent stem cell biology rather than IDPs.

Emerging players

• CrIA Cubiq (Cradle Bio): Cradle applies generative AI to protein engineering and biologic design. It is an emerging player in AI-driven protein science that overlaps with Topos Bio's focus on dynamic proteins, though it focuses on engineering novel proteins rather than targeting disordered ones with small molecules.
• Generate Biomedicines: Generate Biomedicines uses generative AI to design novel protein therapeutics. It is an emerging player in AI-driven biologic design; while focused on de novo proteins rather than IDP-targeted small molecules, it competes for similar AI-bio investor capital and addresses complementary parts of the undruggable-proteome opportunity.

Broad incumbents

• XtalPi: XtalPi combines AI, quantum physics, and robotic experimentation for drug discovery and has established major partnerships with global pharma. It is a broad incumbent in AI + physics-based drug discovery with significantly more capital and a more mature commercial footprint than Topos Bio.
• Schrödinger: Schrödinger is a publicly traded computational chemistry and physics-based drug discovery platform with a broad pharma customer base. It is a broad incumbent providing similar physics-based molecular modeling and ensemble-aware simulation capabilities that compete with Topos-1's value proposition for pharma partners.
• Isomorphic Labs: Isomorphic Labs is Alphabet's drug discovery spinout applying DeepMind's protein structure prediction advances (AlphaFold) to therapeutic development. It is a broad incumbent in AI-driven structure-based drug discovery, with substantially greater resources and competing approaches to the same undruggable-target problem Topos Bio addresses.

Others

• DeepMind (AlphaFold): DeepMind developed AlphaFold, the leading static protein structure predictor against which Topos-1 benchmarks. Although not a direct commercial competitor, DeepMind's open releases set the technical baseline for AI protein modeling and indirectly constrain the commercial defensibility of any AI protein discovery platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Topos Bio